TheraRadar
← Back
Data updated: Jun 28, 2026

AIR LIQUIDE AMERICA LP

Pharma
Pharmaceuticals

AIR LIQUIDE AMERICA LP is a pharmaceutical company with 3 FDA-approved products.

2013
Since
3
Drugs
-
Trials
2
New Drugs (2yr)
Modality:
3 Small Molecules

AIR LIQUIDE AMERICA LP's Key Drugs

AIR LIQUIDE AMERICA LP's core commercial portfolio centers on OXYGEN, USP, MEDICAL AIR, USP, NITROGEN, NF — its most strategically important drugs approved in the last 15 years.

OXYGEN, USP
Respiratory
Approved 2013
MEDICAL AIR, USP
Respiratory
Approved 2013
NITROGEN, NF
Other
Approved 2013

AIR LIQUIDE AMERICA LP's Recent FDA Approvals

AIR LIQUIDE AMERICA LP secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

MEDICAL AIR, USP NDA
2026-02-17
MEDICAL AIR, USP NDA
2024-07-13
medical air

AIR LIQUIDE AMERICA LP's Therapeutic Areas

Disease areas where AIR LIQUIDE AMERICA LP has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

AIR LIQUIDE AMERICA LP Pipeline Snapshot

Active clinical trials for AIR LIQUIDE AMERICA LP across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • OXYGEN, USP leads revenue
  • • 3 key drugs tracked

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling